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METHODS: We compared baseline and 1-month post-
intervention scores from the SF-36 from two previously
reported study groups: headache patients at a headache
clinic (individualized therapy group) and headache suf-
ferers attending headache seminars at their workplaces
(education group). Research using the SF-36 determined
that the domains of role—physical, bodily pain, role—
emotional, and social functioning are most impacted by
chronic headache. For ethical reasons, the individualized
treatment group was not treated with education alone,
therefore their scores are shown for comparison only. No
statistical analysis was performed.
RESULTS: In this study 461 consecutive new patients
seeking headache care at the Cleveland Clinic Headache
Center were compared with 368 headache sufferers at-
tending headache seminars at their workplaces. Both
groups had similar ages, gender mix, and duration of
headache. The individualized therapy group had signifi-
cantly lower SF-36 scores at baseline.
CONCLUSIONS: The patient education component of
headache treatment has a measurable and clinically sig-
nificant impact on health-related quality of life as mea-
sured by the SF-36. Patient education appears to have as
significant a role as comprehensive treatment in the key
headache domain of role–emotional. In other mental
health domains, education alone appears to have a major
influence on improvement. In physical domains such as
bodily pain and role–physical, the impact of pharmaco-
logic therapy appears to have a greater impact.
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Awareness of acetaminophen-related liver toxicity has
been growing. However, its frequency and cost have not
been well documented on a population basis. 
OBJECTIVE: To estimate the incidence and costs of
hepatotoxicity related to acetaminophen use for the Cali-
fornia Medicaid program (Medi-Cal). 
METHODS: This study was based on administrative
claims data for a 10% random sample of Medi-Cal recip-
ients in 1996. Individuals with one or more inpatient or
outpatient claims in 1996 with ICD-9-CM diagnoses of
acetaminophen-related liver toxicity were selected for in-
clusion in this analysis. An episode of treatment was de-
fined as the period of time between the dates of hospital
admission and discharge for which at least one qualifying
diagnosis was listed, or as a day of outpatient treatment
on which a patient had a qualifying diagnosis. All ser-
vices occurring during an episode were assumed to be re-
lated to acetaminophen liver toxicity.
RESULTS: A total of 244 recipients in our 10% sample
had one or more treatment episodes of acetaminophen-
related liver toxicity during 1996 (approximately 41 per-
sons per 100,000 eligibles), and over half of these oc-
curred in persons under 21 years of age. Approximately
20% of patients required admission to a hospital for
treatment. The average cost per patient with liver toxicity
was estimated to be approximately $1070. 
CONCLUSIONS: Based on our estimates of incidence
and per-person expenditures, annual spending by the
Medi-Cal program for acetaminophen-related hepatotox-
icity is projected to be approximately $2.6 million in
1996. The actual incidence of this problem is likely to be
greater than that reported here, since this study only in-
cludes poisonings that led to a medical encounter rather
than all possible occurrences.
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Measuring quality of life (QoL) has become a vital part
of assessing effects of migraine treatment in many inter-
national studies. However, only recently have measures
assessing patients’ perceptions of and satisfaction with
migraine treatment been available and none with linguis-
tically validated translations. Prior to use in an interna-
tional trial, the PPMQ (developed in US English) under-
went linguistic validation in 16 languages. 
METHODS: A QOL specialist coordinated the transla-
tion process of the PPMQ in each target country using
the following methodology: 1) two forward translations
by professional, native speaking translators of the target
language who were fluent in English; 2) comparison and
reconciliation of the translations by a QOL specialist and
translators; 3) backward translation by a native English
speaker; 4) comparison of the source and backward ver-
sion; 5) review of the translation by a clinician in each
country; 6) international harmonization. 
RESULTS: Linguistic, conceptual, and cultural issues
emerged when translating idiomatic phrases and response
scales. “How consistently the medication prevented pain
from coming back” had to be expressed through “reli-
ably” or “constantly.” Cultures less used to completing
questionnaires had difficulty understanding instructions
inviting respondents to express satisfaction with medica-
Change from baseline SF-36 score
Domain Education Individualized therapy
Physical functioning 0.3 2.5
Role–Physical 6.1 11.4
Bodily pain 3.9 9.1
General health 1.8 1.8
Vitality 4.4 2.8
Social functioning 5.5 9.2
Role–Emotional 7.5 7.5
Mental health 1.9 3.2
